Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 11 | 2025 | 287 | 2.010 |
Why?
|
| Colectomy | 4 | 2025 | 35 | 0.990 |
Why?
|
| Ileus | 1 | 2023 | 14 | 0.830 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 163 | 0.730 |
Why?
|
| Abdominal Muscles | 1 | 2021 | 12 | 0.680 |
Why?
|
| Anesthesia, Conduction | 1 | 2021 | 15 | 0.680 |
Why?
|
| Neuromuscular Blockade | 1 | 2021 | 14 | 0.680 |
Why?
|
| Colorectal Surgery | 3 | 2025 | 16 | 0.610 |
Why?
|
| Length of Stay | 2 | 2025 | 673 | 0.580 |
Why?
|
| ABO Blood-Group System | 1 | 2012 | 16 | 0.390 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 185 | 0.390 |
Why?
|
| Patient Readmission | 2 | 2024 | 249 | 0.360 |
Why?
|
| Laparoscopy | 2 | 2025 | 180 | 0.360 |
Why?
|
| Mass Screening | 3 | 2020 | 354 | 0.360 |
Why?
|
| Retrospective Studies | 9 | 2025 | 6695 | 0.350 |
Why?
|
| Registries | 2 | 2025 | 639 | 0.350 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 147 | 0.330 |
Why?
|
| Tertiary Care Centers | 2 | 2025 | 83 | 0.280 |
Why?
|
| Male | 16 | 2025 | 26882 | 0.260 |
Why?
|
| Female | 17 | 2025 | 28286 | 0.260 |
Why?
|
| Postoperative Complications | 2 | 2025 | 1066 | 0.260 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2020 | 96 | 0.250 |
Why?
|
| Middle Aged | 13 | 2025 | 13136 | 0.250 |
Why?
|
| Rectal Diseases | 1 | 2025 | 11 | 0.240 |
Why?
|
| Povidone-Iodine | 1 | 2025 | 8 | 0.230 |
Why?
|
| Ghana | 4 | 2025 | 8 | 0.230 |
Why?
|
| Appendectomy | 1 | 2025 | 37 | 0.230 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2025 | 29 | 0.230 |
Why?
|
| Humans | 19 | 2025 | 52459 | 0.230 |
Why?
|
| Poverty Areas | 1 | 2025 | 41 | 0.220 |
Why?
|
| Aged | 10 | 2025 | 10243 | 0.220 |
Why?
|
| Vitamin B Complex | 1 | 2024 | 22 | 0.220 |
Why?
|
| Choline | 1 | 2024 | 64 | 0.220 |
Why?
|
| Appendicitis | 1 | 2025 | 65 | 0.220 |
Why?
|
| Surgical Wound Infection | 1 | 2025 | 118 | 0.220 |
Why?
|
| Anastomotic Leak | 1 | 2023 | 11 | 0.210 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 80 | 0.210 |
Why?
|
| Adult | 8 | 2025 | 14212 | 0.190 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 768 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2025 | 218 | 0.190 |
Why?
|
| Anticoagulants | 1 | 2025 | 276 | 0.180 |
Why?
|
| Adenocarcinoma | 1 | 2025 | 403 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2024 | 1201 | 0.180 |
Why?
|
| Pesticides | 1 | 2021 | 21 | 0.170 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 52 | 0.170 |
Why?
|
| Survival Rate | 3 | 2025 | 944 | 0.160 |
Why?
|
| Narcotics | 1 | 2021 | 109 | 0.160 |
Why?
|
| Diet | 1 | 2024 | 591 | 0.160 |
Why?
|
| Ultrasonography, Mammary | 1 | 2020 | 61 | 0.160 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 118 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2021 | 111 | 0.160 |
Why?
|
| Incidence | 3 | 2021 | 1097 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2025 | 485 | 0.140 |
Why?
|
| Sacrum | 1 | 2018 | 18 | 0.140 |
Why?
|
| Mandatory Programs | 1 | 2018 | 22 | 0.140 |
Why?
|
| Spinal Neoplasms | 1 | 2018 | 30 | 0.140 |
Why?
|
| Rural Population | 2 | 2025 | 588 | 0.140 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 70 | 0.130 |
Why?
|
| Arkansas | 2 | 2014 | 2014 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 98 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 107 | 0.130 |
Why?
|
| Hospitalization | 1 | 2021 | 731 | 0.120 |
Why?
|
| Physicians | 1 | 2018 | 237 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2025 | 446 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 292 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 20 | 0.100 |
Why?
|
| Fellowships and Scholarships | 2 | 2025 | 123 | 0.100 |
Why?
|
| Rectum | 1 | 2013 | 55 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 52 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 131 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 641 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 151 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1203 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 601 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 3450 | 0.060 |
Why?
|
| Risk Factors | 2 | 2024 | 3972 | 0.060 |
Why?
|
| Hospitals, Urban | 1 | 2025 | 28 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 2100 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2025 | 31 | 0.060 |
Why?
|
| Random Allocation | 1 | 2025 | 286 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2024 | 105 | 0.050 |
Why?
|
| Urban Population | 1 | 2025 | 161 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2025 | 142 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2025 | 656 | 0.050 |
Why?
|
| Poverty | 1 | 2025 | 219 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2024 | 564 | 0.050 |
Why?
|
| Logistic Models | 1 | 2024 | 932 | 0.050 |
Why?
|
| Pesticide Residues | 1 | 2021 | 7 | 0.040 |
Why?
|
| Herbicides | 1 | 2021 | 11 | 0.040 |
Why?
|
| Democratic Republic of the Congo | 1 | 2020 | 4 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2024 | 470 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 35 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 33 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 104 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 86 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 1349 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 137 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2025 | 2436 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 404 | 0.040 |
Why?
|
| Occult Blood | 1 | 2017 | 23 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1029 | 0.030 |
Why?
|
| Morbidity | 1 | 2018 | 137 | 0.030 |
Why?
|
| Rural Health | 1 | 2017 | 85 | 0.030 |
Why?
|
| United States | 2 | 2018 | 5215 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 595 | 0.030 |
Why?
|
| Young Adult | 1 | 2025 | 4349 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 609 | 0.030 |
Why?
|
| Adolescent | 1 | 2025 | 6714 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2294 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 871 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1224 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 5508 | 0.020 |
Why?
|